Vitex (Chasteberry) — Research Profile

Most clinical trials show meaningful improvement after 2-3 menstrual cycles (2-3 months) of daily use. The Schellenberg (2001) trial measured outcomes at 3 cycles. Some women notice changes in the first cycle, but the full effect on hormonal balance and symptom relief typically requires consistent use over multiple cycles. Vitex is not a fast-acting remedy — it works by gradually normalizing the hypothalamic-pituitary-ovarian axis.

Vitex may support fertility in women whose infertility is related to luteal phase defects or mild hyperprolactinemia. By normalizing prolactin and improving progesterone production in the second half of the cycle, it can create a more favorable environment for implantation. However, it should not be used as a standalone fertility treatment. Women actively trying to conceive should work with a healthcare provider and discontinue vitex once pregnancy is confirmed.

Vitex is generally not recommended alongside hormonal contraceptives. Because vitex modulates prolactin and can influence progesterone levels, it may theoretically interfere with the mechanism of hormonal birth control. Most practitioners advise against combining them. If you are using hormonal contraception and want to try vitex, consult your healthcare provider first.

The form with the strongest human evidence is a concentrated, standardized dried-fruit extract (Ze 440) taken as a 20 mg once-daily tablet, which is what the BMJ randomized trial used. Tinctures, teas, and whole-berry powders have far less trial support and deliver less predictable amounts of the active diterpenes.

The best-supported benefit is relief of premenstrual syndrome, including cyclical breast pain and tenderness: in the BMJ trial 52% of women responded versus 24% on placebo (P<0.001). A systematic review of 14 placebo-controlled trials found a large pooled effect (Hedges g -1.21) but cautioned that most trials carry a high risk of bias, which precludes a definitive conclusion. NCCIH likewise describes the supporting human studies as low-to-moderate quality and says higher-quality evidence is needed before any firm conclusions can be drawn. Claims for infertility, menopause, and other uses remain unproven.

The most rigorously studied regimen is 20 mg once daily of the standardized Ze 440 extract, the dose used in the BMJ PMS trial. There is no official recommended intake or upper limit, and non-standardized preparations vary widely in strength, so dosing should follow the specific standardized product's label rather than a universal milligram figure.

Trials dosed it as a single tablet once daily and did not compare morning versus evening, so no time of day has been shown to work better. Because it is taken continuously to influence the whole menstrual cycle rather than for an acute effect, most trial participants simply took it once each day at a fixed time.

Reported side effects are usually mild and include nausea, stomach pain, diarrhea, headache, and itching; MSKCC additionally lists menstrual changes, acne, and skin rash. In the controlled PMS trial, adverse events occurred at similar rates on chasteberry and placebo and none led to stopping treatment.

Yes. Because it acts on dopamine receptors, chasteberry may interfere with dopaminergic drugs such as antipsychotics and Parkinson's (antiparkinson) medications, and it can reduce the effectiveness of oral contraceptives and hormone therapy. It also inhibits the liver enzymes CYP2C19 and CYP3A4, which can alter blood levels of drugs cleared by those pathways, so anyone on hormonal, dopaminergic, or CYP-dependent medication should have it reviewed against their prescriptions before combining.

It is aimed at menstruating women seeking relief from premenstrual syndrome, particularly cyclical breast pain, where the trial evidence is strongest. It should be avoided during pregnancy and breastfeeding and by anyone with a hormone-sensitive condition such as breast, uterine, or ovarian cancer, given its prolactin-lowering and phytoestrogenic activity.

Chasteberry is not fast-acting: the pivotal BMJ randomized trial measured its effect only after three consecutive menstrual cycles, and a systematic review of PMS trials required a minimum of two cycles of treatment for inclusion. It works gradually by lowering prolactin across successive cycles, so most people need roughly two to three cycles (about two to three months) to judge whether it helps.

Controlled studies have only established tolerability for about three months of continuous use, and no trial has documented the effects of years of daily intake. Because chasteberry deliberately alters prolactin and acts on hormonal pathways, extended use without periodic reassessment is not backed by long-term safety data.

There is no established upper limit or documented toxic dose, and at the standard 20 mg/day the pivotal trial reported only mild, transient adverse events (nausea, headache, itching) at rates similar to placebo. Higher intakes have not been formally tested; because the herb suppresses prolactin through dopamine D2 receptors, exceeding studied doses is more likely to amplify hormonal and dopaminergic effects than to add benefit.

No clinical trials have tested chasteberry alongside other supplements, so combinations are poorly characterized. The clearest caution is stacking it with other hormonally active or prolactin-lowering/phytoestrogenic botanicals, since chasteberry itself acts on the pituitary-hypothalamic axis and such combinations could compound its endocrine effects unpredictably.

Choose a product that names a standardized fruit extract rather than raw berry powder. The best-studied preparation is Ze 440, a 6-12:1 dried extract made with 60% ethanol and standardized to the marker compound casticin. Labels specifying the extract ratio and a marker (casticin or agnuside) match what produced positive results in the PMS trials, whereas unstandardized chaste tree berry powders were not what those studies tested.